TrialBlood advances2025

Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML.

Giovanni Marconi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.